A 15-year follow-up study of patients with panic disorder. A prospective naturalistic study of 326 panic-agoraphobic patients treated with antidepressants. Relationship of past depressive episodes to symptom severity and treatment response in panic disorder with agoraphobia. Impact of cognitive-behavioral treatment on quality of life in panic disorder patients. Internet-based self-help treatment for panic disorder: a randomized controlled trial comparing mandatory versus optional complementary psychological support Rate of improvement during and across three treatments for panic disorder with or without agoraphobia: cognitive behavioral therapy, selective serotonin reuptake inhibitor or both combined. Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders. An open study of the effectiveness of Internet treatment for panic disorder delivered in a psychiatric setting SECOND-STAGE TREATMENTS FOR RELATIVE NONRESPONDERS TO COGNITIVE BEHAVIORAL THERAPY (CBT) FOR PANIC DISORDER WITH OR WITHOUT AGORAPHOBIA-CONTINUED CBT VERSUS SSRI: A RANDOMIZED CONTROLLED TRIAL. A three-year follow-up study of patients with the respiratory subtype of panic disorder after treatment with clonazepam A Naturalistic Long-Term Comparison Study of Selective Serotonin Reuptake Inhibitors in the Treatment of Panic Disorder The sequence of improvement of the symptoms encountered in patients with panic disorder. Antidepressant discontinuation in the context of cognitive behavioral treatment for panic disorder. Asthma and panic attacks Medical illness and response to treatment in primary care panic disorder. A randomized clinical trial of cognitive behavioral therapy and interpersonal psychotherapy for panic disorder with agoraphobia. A comparison of bibliotherapy and group therapy in the treatment of panic disorder.
BACKGROUND Panic disorder ( PD ) is generally regarded as a chronic condition with considerable variation in severity of symptoms . AIMS To describe the long-term outcome of naturalistically treated PD . METHODS Fifty-five out patients with PD , who participated in a placebo-controlled drug trial of the efficacy of alprazolam and imipramine 15 years ago were reassessed with the same instruments used in the original study . RESULTS Complete recovery ( no panic attacks and no longer on medication during the last 10 years ) was seen in 18 % of patients , and an additional 13 % recovered but were still on medication . Fifty-one percent experienced recurrent anxiety attacks whereas 18 % still met diagnostic criteria for PD . The incidence of agoraphobia decreased from 69 % to 20 % . Patients with agoraphobia at admission tended to have a poorer long-term outcome according to daily functioning compared with patients without agoraphobia at admission , although both groups reported improved daily functioning at follow-up . Maintenance medication was common . No benzodiazepine abuse was reported . CONCLUSION PD has a favourable outcome in a substantial proportion of patients . However , the illness is chronic and needs treatment . The short-term treatment given in the drug trial had no influence on the long-term outcome OBJECTIVE How far the results of r and omized controlled studies apply to everyday care can not be judged without regular measurements of outcomes in daily practice . We report on systematic data from a 3-year naturalistic prospect i ve study on panic disorder-agoraphobic ( PDA ) patients treated with antidepressants in a setting of routine clinical practice . Our aim is to describe the evolution of PDA in relation to the treatments employed , and to explore demographic and clinical characteristics that might be predictive of outcome . METHODS 326 DSM-III-R PDA patients treated with antidepressants in a setting of routine clinical practice were included in a 3-year naturalistic prospect i ve study . We utilized structured and semi-structures instruments , including the Structured Clinical Interview for Diagnosis and the Longitudinal Interview Follow-up Examination . The main antidepressants used were imipramine ( 39 % ) , clomipramine ( 28.5 % ) and paroxetine ( 23.3 % ) ; only 9 % of patients received other antidepressants . RESULTS 147 patients ( 45.1 % ) stayed on medication throughout the entire period of the follow-up . Of those who interrupted the treatment , 38 % stayed in remission . The probability of achieving at least one remission during the 3-year follow-up period was 96.5 % for PD and 95.9 % for Agoraphobia . Relapses after a period of at least 2 months of complete remission were also common , and the probability of presenting at least one relapse during the 3-years follow-up period was 67.1 % for PD and 39 % for Agoraphobia . The longest period of remission of PD is associated with low severity , medium-lasting course in patients with an onset of the illness in young adulthood . Less severe agoraphobia associated with moderately severe panic attacks appears to confer a better control of phobic behavior . All three major drugs were reasonably well tolerated ( only 9 % dropped out because of side effects ) , with sexual dysfunction and increased appetite being the most common side effects at the last evaluation ; in the first phase of the treatment anticholinergic effects and jitteriness were more common with TCAs . CONCLUSION Both classical antidepressants and paroxetine emerge as a useful treatment in the long-term management of PDA ; paroxetine appears particularly useful in PDA patients because it was significantly less likely to induce jitteriness , thereby reducing barriers to compliance BACKGROUND Many investigators have reported that panic disorder ( PD ) patients with comorbid major depression ( MD ) have more severe symptoms and a poorer response to treatment than patients with PD alone . It is not known if this is due to a distinct and more serious underlying disorder in these patients or simply a result of the simultaneous presence of the two disorders . METHOD Nondepressed patients presenting for treatment of panic disorder with agoraphobia ( PDA ) were studied before treatment ( N = 180 ) and after 4 weeks of treatment with adinazolam sustained release ( N = 89 ) or placebo ( N = 91 ) . Twenty-nine percent ( N = 53 ) of the patients had a past history of MD .  Symptom severity and treatment outcome were compared in patients with primary , secondary , single , recurrent , or no past MD . RESULTS There were no consistent differences in symptom severity or treatment outcome in patients with a past history of primary , secondary , or single episode MD compared with patients with no history of MD . However , a small number of patients with history of recurrent MD exhibited consistently greater symptom severity and poorer response to treatment than patients with no history of MD . CONCLUSION The greater severity and worse outcome of comorbid PD and MD observed in earlier studies are more likely due to the simultaneous presence of the two disorders than to a more serious and enduring underlying disorder . However , our results suggest that recurrent MD may indicate a more serious condition in patients with PDA . This possibility warrants further study Panic disorder ( PD ) is associated with significant social and health consequences . The present study examined the impact of treatment on PD patients '  quality of life . Patients ( N = 156 ) meeting DSM-III-R ( Diagnostic and Statistical Manual of Mental Disorders [ 3rd ed . , rev . ] ; American Psychiatric Association , 1987 ) criteria for PD with agoraphobia were r and omly assigned to group cognitive-behavioral treatment ( CBT ) or a delayed-treatment control . An assessment battery measuring the major clinical features of PD as well as quality of life was administered at baseline ( Week 0 ) , post-treatment ( Week 9 ) and 6-month follow-up ( Week 35 ) . Consistent with previous studies , PD patients displayed significant impairment in quality of life at intake . Compared with delayed-treatment control participants , CBT-treated participants showed significant reductions in impairment that were maintained at follow-up . Consistent with prediction , anxiety and phobic avoidance were significantly associated with quality of life , whereas frequency of panic attacks was not Abstract Panic disorder ( PD ) is one of the most common psychiatric disorders . Web-based self-help treatments for PD have had promising results . These online treatments seem to have larger effect sizes ( ESs ) when professional support is added . However , the amount of support or how it should be administered is not yet clear . The aim of this trial was to study two ways of administering psychological support provided by phone as a part of Internet-based self-help treatment for PD based on cognitive behavioral therapy .  Seventy-seven participants diagnosed with PD were r and omly assigned to one of three experimental conditions : a waiting list control group ; a treatment group with non-scheduled psychological support ; or a treatment group with scheduled psychological support .  PD symptoms of participants who received treatment improved significantly compared to the control group ( mean ES d = 1.18 , p < .05 ) . In addition , there were statistically and clinical ly significant differences between treatment groups ( Mean difference = −3.20 , p = .005 , 95 % CI [ −5.62 , −.79 ] ) . The scheduled group showed a larger ES , a lower dropout rate , and better adherence to treatment than the non-scheduled group .  Scheduled support  seems to be indicated for patients who seek Web-based treatment for PD , and their symptoms of panic , anxiety , and depression improve at post-treatment and six-month follow-up . In contrast , when support depends on patient dem and , they receive less support and so , the therapeutic effect is poorer BACKGROUND Existing literature on panic disorder ( PD ) yields no data regarding the differential rates of improvement during Cognitive Behavioral Therapy ( CBT ) , Selective Serotonin Reuptake Inhibitor ( SSRI ) or both combined ( CBT+SSRI ) . METHOD Patients were r and omized to CBT , SSRI or CBT+SSRI which each lasted one year including three months of medication taper . Participating patients kept record of the frequency of panic attacks throughout the full year of treatment . Rate of improvement on panic frequency and the relationship between rate of improvement and baseline agoraphobia ( AG ) were examined . RESULTS A significant decline in frequency of panic attacks was observed for each treatment modality . SSRI and CBT+SSRI were associated with a significant faster rate of improvement as compared to CBT . Gains were maintained after tapering medication . For patients with moderate or severe AG , CBT+SSRI was associated with a more rapid improvement on panic frequency as compared to patients receiving either mono-treatment . LIMITATIONS Frequency of panic attacks was not assessed beyond the full year of treatment . Second , only one process variable was used . CONCLUSIONS Patients with PD respond well to each treatment as indicated by a significant decline in panic attacks .  CBT is associated with a slower rate of improvement as compared to SSRI and CBT+SSRI . Discontinuation of SSRI treatment does not result in a revival of frequency of panic attacks . Our data suggest that for patients without or with only mild AG , SSRI-only will suffice . For patients with moderate or severe AG , the combined CBT+SSRI treatment is recommended OBJECTIVE Major depression occurs with generalized anxiety disorder and panic disorder in up to 60 % of psychiatric and primary care patients . This comorbidity has been associated with greater severity of depression , poorer psychosocial functioning , and poorer treatment outcomes in psychiatric sample s. This study examined the clinical outcomes for depressed primary care patients with and without a lifetime anxiety disorder . METHOD A total of 157 primary care patients who met criteria for major depression were r and omly assigned to st and ardized interpersonal psychotherapy or pharmacotherapy with nortriptyline and were assessed at baseline and at 4 and 8 months on severity of depression , psychosocial functioning , and health-related functioning . RESULTS Depressed patients with a comorbid anxiety disorder presented with significantly more psychopathology and tended to prematurely terminate treatment more frequently than patients with major depression alone . Both st and ardized depression-specific treatments were effective for depressed patients with and without a comorbid generalized anxiety disorder , although time to recovery was longer for the former . Patients with lifetime panic disorder showed poor recovery in response to psychotherapy or pharmacotherapy . CONCLUSIONS St and ardized psychotherapy and pharmacotherapy are effective for patients with major depression with and without a generalized anxiety disorder . However , the longer time to recovery for the former group and lack of response to these treatments by patients with lifetime panic disorder suggest that primary care physicians should carefully assess history of anxiety disorder among depressed patients so as to select a proper intervention Panic disorder with or without agoraphobia ( PD/A ) is common and can be treated effectively with selective serotonin reuptake inhibitor ( SSRI ) medication or cognitive – behaviour therapy ( CBT ) . However , the lack of access to CBT services has motivated the development of self-help approaches requiring less therapist contact . A novel treatment modality in this field , showing efficacy in several r and omized trials but until now not evaluated within the context of regular psychiatric care , is Internet-based treatment . The aim of the present study was to evaluate the effectiveness of Internet-based CBT  for patients in a psychiatric setting . Twenty consecutively referred patients with PD were included in the study . A structured clinical interview with a psychiatrist was conducted for inclusion , as well as at post-treatment and at the 6-month follow-up . The treatment consisted of a 10-week CBT-based self-help programme , including minimal therapist support by e-mail . At post-treatment , 94 % of patients no longer met DSM-IV criteria for PD ( 82 % at 6-month follow-up ) . The within-group effect sizes ( for the main outcome PDSS ; Panic Disorder Severity Scale ) were Cohen 's d=2.5 ( pre- to post-treatment ) and 2.8 ( pre-treatment to follow-up ) , respectively . The proportion of responders on the PDSS was 75 % at post-treatment and 70 % at 6-month follow-up . The results supports earlier efficacy data on Internet-based CBT for PD and indicates that it is effective also within a regular psychiatric setting . However , a larger r and omized controlled trial should be conducted , directly comparing Internet-based CBT with traditionally administered CBT within such a setting BACKGROUND Cognitive behavioral therapy ( CBT ) and pharmacotherapy are efficacious for the short-term treatment of panic disorder . Less is known about the efficacy of these therapies for individuals who do not respond fully to short-term CBT .  METHOD The current trial is a second-step stratified r and omized design comparing two treatment conditions-selective serotonin reuptake inhibitor ( SSRI ; paroxetine or citalopram ; n = 34 ) and continued CBT  ( n = 24)-in a sample of individuals classified as treatment nonresponders to an initial course of CBT for panic disorder . Participants were r and omized to 3 months of treatment and then followed for an additional 9 months . Only treatment responders after 3 months were maintained on the treatment until 12-month follow-up . Data analysis focused on panic disorder symptoms and achievement of response status across the first 3 months of treatment . Final follow-up data are presented descriptively . RESULTS Participants in the SSRI condition showed significantly lower panic disorder symptoms as compared to continued CBT at 3 months . Results were similar when excluding individuals with comorbid major depression or analyzing the entire intent-to-treat sample . Group differences disappeared during 9-month naturalistic follow-up , although there was significant attrition and use of non study therapies in both arms . CONCLUSIONS These data suggest greater improvement in panic disorder symptoms when switching to SSRI after failure to fully respond to an initial course of CBT . Future studies should further investigate relapse following treatment discontinuation for nonresponders who became responders . Clinical trials.gov Identifier : NCT00000368 ; https:// clinical trials.gov/show/NCT00000368 The demographic , clinical and therapeutic features of the respiratory subtype of panic disorder ( PD ) versus the non-respiratory subtype were studied in a prospect i ve design . Sixty-seven PD out patients ( DSM-IV ) , who had previously been categorized into respiratory ( n=35 ) and non-respiratory ( n=32 ) subgroups , were openly treated with clonazepam for a 3-year period . The principal measure of efficacy was the number of panic attacks , obtained from the Sheehan Panic and Anticipatory Anxiety Scale . In the first 8 weeks of treatment ( acute phase ) , the respiratory subtype group had a significantly faster response to clonazepam . During the follow-up ( weeks 12 - 156 ) , the two subgroups did not differ significantly in the number of panic attacks experienced from baseline to end point . Patients in the respiratory subtype were characterized by a later onset of disorder and a family history of PD . Patients in the non-respiratory subgroup had a significantly higher number of past depressive episodes than those in the respiratory subgroup . The respiratory subgroup had a faster response after 8 weeks of treatment and an equivalent response in the 3-year follow-up period . Clonazepam had a sustained therapeutic effect over the entire treatment period Objectives : Selective serotonin reuptake inhibitors ( SSRIs ) are currently considered as the first drug of choice in the treatment of panic disorder ( PD ) . The aim of this long-term , naturalistic comparison study was to compare 4 SSRIs with respect to tolerability and treatment outcome of PD . Outcome measures included relapse rates and adverse effects . Methods : Two hundred patients with PD were enrolled in our study . All subjects met DSM-IV criteria for PD or PD with agoraphobia ( PDA ) . All patients were assigned to receive SSRI monotherapy for 12 months with either citalopram ( n = 50 ) , fluoxetine ( n = 50 ) , fluvoxamine ( n = 50 ) , or paroxetine ( n = 50 ) in a r and omized , nonblinded fashion . Both the treating psychiatrist and the patients were not blind to the assigned treatment , but the clinician raters were blind to the study medication . The study design allowed for assignment of a particular SSRI as indicated according to the clinical judgment of the study psychiatrists . The Panic Self- Question naire , which is a self-report scale , was administered at baseline and then once per month during the duration of the 12-month study . The visual analog scale and the Clinical Global Impression Scale were administered at baseline and then once per month during the period of the study . Reports of sexual dysfunction were assessed using a nonstructured clinical interview at monthly visits . The body weight of study subjects was measured at baseline , and then at the 12th month visit end point . Results : Of 200 patients who entered the study , 127 patients ( 63.5 % ) completed the full 12-month protocol . Retention rates were highest for paroxetine ( 76 % [ 38/50 ] ) , intermediate for citalopram ( 68 % [ 34/50 ] ) and fluvoxamine ( 60 % [ 30/50 ] ) , and lowest for fluoxetine ( 50 % [ 25/50 ] ) . Patients who completed the 12-month protocol responded favorably to the study treatment . The paroxetine and the citalopram groups had significantly lower rates of panic symptoms as measured at visits on weeks 4 and 8 . At visits on months 3 , 6 , 9 , and 12 , however , there were no statistically significant differences between the 4 groups in relapse rates ( defined as the occurrence of 1 or more panic attacks during the previous week of treatment ) ( F1,127 = 0.17 ; P = 0.13 [ not statistically significant ] ) . At the 12th month end point , patients in all 4 treatment groups had a statistically significant increase in body weight . Body weight among the study population increased by 6.1 + 4.9 kg from a mean weight of 72.4 + 7.3 kg at the onset of treatment . Reports of sexual adverse effects at the 12th month visit were similar in the citalopram , fluoxetine , and paroxetine groups , but the fluvoxamine patient group reported fewer sexual adverse effects at the 12th month visit . Conclusions : Most of our PD patients responded well to 12-month treatment with either citalopram , fluoxetine , fluvoxamine , or paroxetine , and the overall response rate was equal after the first 4 weeks of treatment . Although patients treated with paroxetine had the lowest dropout rates during the initiation phase , they had the highest rate of adverse effects as measured at the 12th month visit . Conversely , patients in the fluvoxamine group had the highest dropout rate ( which was primarily caused by adverse effects in the initiation phase of treatment . ) ; however , patients who were able to tolerate fluvoxamine throughout the full course of the study were observed to have lower rates of sexual dysfunction and weight gain compared with patients treated with the other agents . Overall , when measured at the 12th month visit , monotherapy with paroxetine and citalopram was associated with a higher rate of sexual adverse effects than was treatment with fluoxetine or fluvoxamine . In addition , monotherapy with paroxetine , citalopram , and fluoxetine seemed to cause more weight gain than did treatment with fluvoxamine Patients who meet DSM-III-R criteria for a diagnosis of panic disorder often show a complex mixture of psychopathological symptoms , including panic attacks ( spontaneous and situational ) , anxiety ( anticipatory and generalized ) , phobias ( fear and avoidance ) , depression/dysphoria , and social and occupational disability . Various theories about the pathogenesis of these symptoms have been advanced that focus on a given symptom ( e.g. , panic , phobia ) being primary in these disorders , with concurrent symptoms seen as epiphenomena or as secondary and reactive to a core symptom . This study , conducted on a large sample of panic disorder patients ( N = 1,168 ) , examines the temporal sequential pattern of symptom improvement in these patients , and explores how these relationships relate to various pathogenic theories . Our multiple analyses , when considered together , tend not to support any pathogenic theory that views a given symptom as being central to the overall disorder ; our findings have obvious implication s for theoreticians and clinicians interested in the study and treatment of panic and anxiety disorders Cognitive behavioral treatment ( CBT ) has been shown to reduce risk for adverse reactions ( e.g. , rebound panic ) following benzodiazepine taper for patients with panic disorder ( PD ) . This study evaluated the effects of antidepressant discontinuation for patients with PD in the context of CBT .  Patients with PD ( n=21 ) on a stable dose of antidepressants completed a 12-week group CBT treatment and were r and omly assigned to discontinue antidepressants during week 8 of the treatment . There were no statistically significant differences between groups at posttreatment or 6-month follow-up . Data indicate no apparent immediate or long-term adverse effects for antidepressant discontinuation for patients with PD receiving CBT Panic disorder ( PD ) and asthma share many common characteristics and have been found in epidemiological studies to be significantly comorbid . To investigate possible reasons for this overlapping , the authors evaluated 51 patients with asthma , assessing the prevalence of PD and sporadic panic attacks , the temporal relationship between these two disorders , and the familial risk for PD in the families of asthmatics . The results showed significantly higher prevalences of PD , sporadic panic attacks , and social phobia in asthmatics than those reported for the general population . In 9 ( 90 % ) of the asthmatics with PD , asthma appeared first . Finally , the morbidity risk for PD in families of asthmatics with PD ( 13.5 % ) was significantly higher than in families of asthmatics without evidence of panic ( 2 % ) . Our results suggest that the high prevalence of PD in asthmatics might be related to a facilitating effect of asthma on the development of PD in subjects with familial predisposition to PD OBJECTIVE Although studies have suggested that comorbid medical illness can affect the outcome of patients with depression , little is known about whether medical illness comorbidity affects treatment outcome in patients with anxiety . METHOD Primary care patients with panic disorder ( n=232 ) , participating in a r and omized collaborative care intervention of CBT and pharmacology  , were divided into those above ( n=125 ) and below ( n=107 ) the median for burden of chronic medical illness and assessed at 3 , 6 , 9 and 12 months . RESULTS Subjects with a greater burden of medical illness were more psychiatrically ill at baseline , with greater anxiety symptom severity , greater disability and more psychiatric comorbidity . The intervention produced significant and similar increases in amount of evidence -based care , and reductions in clinical symptoms and disability that were comparable in the more and less medically ill groups . CONCLUSIONS The comparable response of individuals with more severe medical illness suggests that CBT and pharmacotherapy for panic disorder work equally well regardless of medical illness comorbidity . However , the more severe psychiatric illness both at baseline and follow-up in these same individuals suggest that treatment programs may need to be extended in time to optimize treatment outcome BACKGROUND Interpersonal psychotherapy ( IPT ) seems to be as effective as cognitive behavioral therapy ( CBT ) in the treatment of major depression . Because the onset of panic attacks is often related to increased interpersonal life stress , IPT has the potential to also treat panic disorder . To date , a preliminary open trial yielded promising results but there have been no r and omized controlled trials directly comparing CBT and IPT for panic disorder . METHOD This study aim ed to directly compare the effects of CBT versus IPT for the treatment of panic disorder with agoraphobia . Ninety-one adult patients with a primary diagnosis of DSM-III or DSM-IV panic disorder with agoraphobia were r and omized . Primary outcomes were panic attack frequency and an idiosyncratic behavioral test . Secondary outcomes were panic and agoraphobia severity , panic-related cognitions , interpersonal functioning and general psychopathology . Measures were taken at 0 , 3 and 4 months ( baseline , end of treatment and follow-up ) . RESULTS Intention-to-treat ( ITT ) analyses on the primary outcomes indicated superior effects for CBT in treating panic disorder with agoraphobia . Per- protocol analyses emphasized the differences between treatments and yielded larger effect sizes . Reductions in the secondary outcomes were equal for both treatments , except for agoraphobic complaints and behavior and the credibility ratings of negative interpretations of bodily sensations , all of which decreased more in CBT . CONCLUSIONS CBT is the preferred treatment for panic disorder with agoraphobia compared to IPT . Mechanisms of change should be investigated further , along with long-term outcomes This study investigated 2 methods of disseminating a cognitive-behavioral intervention for panic disorder ( PD ) . Thirty-six Ss who met diagnostic criteria for PD according to the Anxiety Disorders Interview Schedule-Revised were r and omly assigned to 1 of 3 conditions : bibliotherapy ( BT ) , group therapy ( GT ) , or a waiting-list control ( WL ) condition . Interventions lasted 8 weeks and were followed by a posttest , along with 3- and 6-month follow-up assessment s. Results indicated that both the BT and GT treatments were more effective than the WL condition in reducing frequency of panic attacks , severity of physical panic symptoms , catastrophic cognitions , agoraphobic avoidance , and depression and that the BT and GT treatments were more effective in increasing self-efficacy . Both interventions maintained their effects throughout the follow-up periods and produced clinical ly significant levels of change among the majority of treated Ss
These drugs were better tolerated than tricyclics and benzodiazepines as they had a low risk of dependence and overdosing complications .
The serotonergic , noradrenergic and GABAergic pathways play a major role in the fear network and in the physiopathology of PD .
INTRODUCTION Panic disorder ( PD ) is a prevalent psychiatric disorder characterized by unexpected and recurrent panic attacks .
PD patients present significant psychosocial impairment and a high risk of psychiatric comorbidities and suicide .
PD should be treated effectively as soon as the symptoms emerge because the longer these patients remain without treatment , the worse the prognosis will be .
SSRIs and SNRIs are the first-line compounds in the treatment of PD .